Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GRAM domain containing 4 pseudogene 2 (GRAMD4P2) is a non-coding processed pseudogene locus in the human genome, located at chromosome 17p13.1. Pseudogenes like GRAMD4P2 arise either by retrotransposition (processed pseudogenes), or duplication and subsequent loss of function. GRAMD4P2 is annotated as a processed pseudogene per HGNC and NCBI standards, meaning it is a genomic sequence derived from a functional parent gene but mutated such that it cannot produce a functional protein. Pseudogenes occasionally play roles in regulating their parent genes via RNA mechanisms—such as serving as miRNA decoys or through siRNA-mediated processes—but there is no described functional activity, disease association, or regulatory significance specifically attributed to GRAMD4P2 in the current literature. Therefore, it is not considered a therapeutic target, biomarker, or associated with safety concerns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GRAM domain containing 4 pseudogene 2 (GRAMD4P2).